Live

China retaliated with 34% tariffs on US goods, while Trump vows his policies will 'never change.'

LSE - Delayed Quote USD

AstraZeneca PLC (0A4J.L)

Compare

74.90

-2.49

(-3.22%)

At close: March 12 at 1:57:50 PM GMT

AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?

AstraZeneca's (LON:AZN) stock up by 7.5% over the past three months. Since the market usually pay for a company’s...

Simply Wall St. 5 hours ago

AZN

AZNCF
Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs

Here are some notable moves across sectors in global markets, following President Trump’s “Liberation Day” tariffs. Some investors turned to drink: Scotch producer Diageo and Aperol maker Campari were among the few risers in Europe. This is mostly about their imports from Mexico and Canada, brokers say, after the White House kept duty-free access to the U.S. for USMCA-compliant products.

The Wall Street Journal yesterday

NKE

AZN

AZNCF
How Trump's tariffs will impact your finances and the UK economy

Keir Starmer has admitted the US president's trade war will hurt the UK economy.

Yahoo Finance UK yesterday

LVMHF

LVMUY

GBPEUR=X
Trending tickers: Nvidia, Tesla, Nike, AstraZeneca and Standard Chartered

The latest investor updates on stocks that are trending on Thursday.

Yahoo Finance UK yesterday

GBPEUR=X

GBP=X

EUR=X
Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins

The latest investor updates on stocks that are trending on Tuesday.

Yahoo Finance UK 3 days ago

^DJI

GBPEUR=X

GBP=X
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.

Investor's Business Daily 3 days ago

NAMS

NAMSW

AZN
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

WILMINGTON, Del., March 31, 2025--Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care-lipid lowering therapies such as statins.1,2

Business Wire 4 days ago

AZN

AZNCF
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

WILMINGTON, Del., March 31, 2025--AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).

Business Wire 4 days ago

AZN

AZNCF
AstraZeneca says new results reinforce Tagrisso as backbone therapy

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include: LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy; SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with h

TipRanks 8 days ago

AZN

AZNCF
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

WILMINGTON, Del., March 25, 2025--New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include:

Business Wire 9 days ago

AZN

AZNCF
Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden

The upgrade focuses on enhancing the cooling capacity at the plant and supplying supplementary equipment installation.

World Construction Network 10 days ago

AZN
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks 11 days ago

AZN
AstraZeneca to invest $2.5bn in R&D centre in China

The new centre will focus on early-stage research and clinical development, supported by data science and AI labs.

Pharmaceutical Technology 11 days ago

AZN
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead

AstraZeneca (NASDAQ: AZN), a U.K.-based pharmaceutical giant, is one of them; its stock is up by an impressive 16% since January. AstraZeneca's shares fell off a cliff late last year when it announced the arrest of some of its executives in China, including Leon Wang, the drugmaker's president in the country. Last year, its revenue jumped by 18% year over year to $54.1 billion, an excellent performance for a pharmaceutical giant.

Motley Fool 12 days ago

AZN
Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.6% and the Hea

PREMIUM
MT Newswires 13 days ago

AZN

ALNY
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.

Zacks 14 days ago

AZN

HLN

PFE
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 14 days ago

KRYS

AZN
AstraZeneca to invest £2bn in Beijing amid China investigation

AstraZeneca has unveiled plans to invest £2bn in Beijing months after Chinese authorities detained the company’s local boss over alleged illegal activity.

The Telegraph 14 days ago

AZN
Micron, Johnson & Johnson, AstraZeneca: Top Stocks

Morning Brief host Brad Smith tracks several of this morning's trending stocks and market stories, including Micron Technology's (MU) guidance overshadowing its fiscal second quarter results, Johnson & Johnson's (JNJ) plans to invest in US manufacturing, and AstraZeneca's (AZN) own investment into a Beijing facility. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 14 days ago

MU

AZN

AZNCF
AstraZeneca to Invest $2.5 Billion in China Amid Probes

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies, at a time when Chinese authorities are probing it.

The Wall Street Journal 14 days ago

AZN

AZNCF

Performance Overview

Return	0A4J.L	MSCI WORLD (^990100-USD-STRD)
YTD	+14.00%	-9.64%
1-Year	+12.55%	-1.06%
3-Year	+17.64%	+8.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

AstraZeneca PLC (0A4J.L)

AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?

Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs

How Trump's tariffs will impact your finances and the UK economy

Trending tickers: Nvidia, Tesla, Nike, AstraZeneca and Standard Chartered

Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

AstraZeneca says new results reinforce Tagrisso as backbone therapy

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

AstraZeneca to invest $2.5bn in R&D centre in China

Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead

Sector Update: Health Care Stocks Retreat Late Afternoon

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

AstraZeneca to invest £2bn in Beijing amid China investigation

Micron, Johnson & Johnson, AstraZeneca: Top Stocks

AstraZeneca to Invest $2.5 Billion in China Amid Probes

Performance Overview

News

Life

Entertainment

Finance

Sports

New on Yahoo

Live

AstraZeneca PLC (0A4J.L)

AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?

Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs

How Trump's tariffs will impact your finances and the UK economy

Trending tickers: Nvidia, Tesla, Nike, AstraZeneca and Standard Chartered

Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

AstraZeneca says new results reinforce Tagrisso as backbone therapy

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

AstraZeneca to invest $2.5bn in R&D centre in China

Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead

Sector Update: Health Care Stocks Retreat Late Afternoon

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

AstraZeneca to invest £2bn in Beijing amid China investigation

Micron, Johnson & Johnson, AstraZeneca: Top Stocks

AstraZeneca to Invest $2.5 Billion in China Amid Probes

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial